RecruitingNot ApplicableNCT07331753
The Outcomes of Fat Grafting Combined With Latissimus Dorsi Muscle Flap for Delayed Breast Reconstruction After Mastectomy
Sponsor
Sohag University
Enrollment
20 participants
Start Date
Nov 1, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The outcomes of fat grafting combined with latissimus dorsi muscle flap for delayed breast reconstruction after mastectomy
Eligibility
Sex: FEMALEMin Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study is looking at the outcomes of a breast reconstruction technique that combines fat grafting (using the patient's own fat) with a muscle flap from the back (latissimus dorsi) for women who had a mastectomy and are having delayed reconstruction.
**You may be eligible if...**
- You are a female patient who is scheduled for a skin-sparing mastectomy
- You are seeking delayed breast reconstruction after mastectomy
**You may NOT be eligible if...**
- You have stage 4 (metastatic) breast cancer
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
PROCEDUREFat grafting combined with latissimus dorsi muscle flap
Fat grafting combined with latissimus dorsi muscle flap for delayed breast reconstruction
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07331753
Related Trials
Utility of a Mobile Application for Young Women With Breast Cancer
NCT070090931 location
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
NCT0710010645 locations
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
NCT028307241 location
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767150 locations
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
NCT0740580145 locations